



BerGenBio ASA: Extraordinary General Meeting held

Bergen, Norway, 6 January 2022 – BerGenBio ASA (OSE:BGBIO) announces that an extraordinary general meeting in the Company was held on 6 January 2022.

All proposals were resolved as presented in the notice convening the extraordinary general meeting distributed on 16 December 2022, as further set out in the minutes from the extraordinary general meeting attached hereto and available at <https://www.bergenbio.com/investors/general-meetings/>

-Ends-

For further information, please contact:

Martin Olin, CEO, BerGenBio ASA
ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com

Forward looking statements

This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.